NEWRON PHARMACEUTICALS SPA (NP5.DE) Stock Price & Overview
FRA:NP5 • IT0004147952
The current stock price of NP5.DE is 20.8 EUR. Today NP5.DE is up by 1.46%. In the past month the price decreased by -3.93%. In the past year, price increased by 125.84%.
NP5.DE Key Statistics
- Market Cap
- 416.208M
- P/E
- 15.29
- Fwd P/E
- N/A
- EPS (TTM)
- 1.36
- Dividend Yield
- N/A
NP5.DE Stock Performance
NP5.DE Stock Chart
NP5.DE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NP5.DE. When comparing the yearly performance of all stocks, NP5.DE is one of the better performing stocks in the market, outperforming 96.7% of all stocks.
NP5.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to NP5.DE. Both the profitability and the financial health of NP5.DE get a neutral evaluation. Nothing too spectacular is happening here.
NP5.DE Earnings
On September 16, 2025 NP5.DE reported an EPS of 0 and a revenue of 11.90M. The company beat EPS expectations (99.11% surprise) and beat revenue expectations (30.47% surprise).
NP5.DE Forecast & Estimates
10 analysts have analysed NP5.DE and the average price target is 53.22 EUR. This implies a price increase of 155.88% is expected in the next year compared to the current price of 20.8.
For the next year, analysts expect an EPS growth of -200.56% and a revenue growth -66.13% for NP5.DE
NP5.DE Groups
Sector & Classification
NP5.DE Financial Highlights
Over the last trailing twelve months NP5.DE reported a non-GAAP Earnings per Share(EPS) of 1.36. The EPS increased by 231.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.83% | ||
| ROA | 24.79% | ||
| ROE | 1086.63% | ||
| Debt/Equity | 25.32 |
NP5.DE Ownership
NP5.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.38 | 191.556B | ||
| 1SAN | SANOFI | 9.38 | 191.411B | ||
| SAN | SANOFI | 9.2 | 191.363B | ||
| MRK | MERCK KGAA | 13.17 | 53.5B | ||
| UCB | UCB SA | 25.08 | 51.176B | ||
| UNC | UCB SA | 25.58 | 51.176B | ||
| 1BAYN | BAYER AG-REG | 7.67 | 36.806B | ||
| BAYN | BAYER AG-REG | 7.73 | 36.743B | ||
| IPN | IPSEN | 14.43 | 13.72B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.104B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.4 | 10.042B | ||
| VIRP | VIRBAC SA | 16.27 | 2.932B | ||
| DMP | DERMAPHARM HOLDING SE | 15.25 | 2.073B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About NP5.DE
Company Profile
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Company Info
NEWRON PHARMACEUTICALS SPA
via Antonio Meucci 3
Bresso MILANO IT
Employees: 22
Phone: 39026103461
NEWRON PHARMACEUTICALS SPA / NP5.DE FAQ
Can you describe the business of NEWRON PHARMACEUTICALS SPA?
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
What is the stock price of NEWRON PHARMACEUTICALS SPA today?
The current stock price of NP5.DE is 20.8 EUR. The price increased by 1.46% in the last trading session.
Does NP5 stock pay dividends?
NP5.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of NP5 stock?
NP5.DE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the Price/Earnings (PE) ratio of NEWRON PHARMACEUTICALS SPA (NP5.DE)?
The PE ratio for NEWRON PHARMACEUTICALS SPA (NP5.DE) is 15.29. This is based on the reported non-GAAP earnings per share of 1.36 and the current share price of 20.8 EUR.
What is the next earnings date for NP5 stock?
NEWRON PHARMACEUTICALS SPA (NP5.DE) will report earnings on 2026-03-24, after the market close.